BUZZ-Plus Therapeutics rises as FDA grants orphan drug tag for pediatric brain cancer treatment
Reuters04-08
BUZZ-Plus <a href="https://laohu8.com/S/LENZ">Therapeutics</a> rises as FDA grants orphan drug tag for pediatric brain cancer treatment
** Shares of biotech firm Plus Therapeutics PSTV.O rise 15% to $3.36 premarket
** Co says the FDA granted orphan drug designation to experimental drug reyobiq for pediatric malignant gliomas, a rare and aggressive childhood brain cancer, which is hard to treat with surgery or chemotherapy alone
** Co says reyobiq delivers targeted radiation directly into tumors to limit damage to healthy brain tissue
** The FDA has cleared the drug for testing in children; studies are also ongoing in other brain cancers and cancer spread to brain fluid - PSTV
** FDA grants orphan drug status to promote drug development for rare diseases affecting fewer than 200,000 people in the U.S.
** As of last close, stock down ~77% YTD
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments